Evaluating the Effects of Sodium Glucose Co-transporter -2 Inhibitors from a Renin-angiotensin-aldosterone System Perspective in Patients Infected with COVID-19: Contextualizing Findings from the Dapagliflozin in Respiratory Failure in Patients With...

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2022 Feb 1

PMID 35102475

Authors

Diala Alhaj Moustafa

Zainab Imran

Roua Ismail

Menatallah Rayan

Alain-Pierre Gadeau

Hussein Eldassouki

Nabeel Abdulrahman

Fatima Mraiche

Affiliations

Soon will be listed here.

Abstract

Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2) inhibitors have garnered substantial attention recently due to their efficacy in reducing the severity of cardiorenal disease. The effect of SGLT-2 inhibitors in patients with COVID-19 remains unclear particularly since SGLT-2 inhibitors contribute to altering the RAAS cascade activity, which includes ACE-2, the major cell entry receptor for SARS-CoV2. A study, DARE-19, was carried out to unveil the effects of SGLT-2 inhibitor treatment on comorbid disease complications and concomitant COVID-19 outcomes and demonstrated no statistical significance. However, the need for further studies is essential to provide conclusive clinical findings.

Citing Articles

Exploring Vaping Patterns and Weight Management-Related Concerns among Adolescents and Young Adults: A Systematic Review.

Mohapatra S, Wisidagama S, Schifano F J Clin Med. 2024; 13(10).

PMID: 38792437 PMC: 11122629. DOI: 10.3390/jcm13102896.

Insulin may increase disease severity and mortality of COVID-19 through Na/H exchanger in patients with type 1 and type 2 diabetes mellitus.

Cure E, Cumhur Cure M J Endocrinol Invest. 2022; 46(4):845-847.

PMID: 36318448 PMC: 9628438. DOI: 10.1007/s40618-022-01951-y.

Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis.

Kim J, Miyazaki K, Shah P, Kozai L, Kewcharoen J Healthcare (Basel). 2022; 10(4).

PMID: 35455823 PMC: 9027687. DOI: 10.3390/healthcare10040645.

VDAC2 as a novel target for heart failure: Ca at the sarcomere, mitochondria and SR.

Rosenberg P Cell Calcium. 2022; 104:102586.

PMID: 35429733 PMC: 9459362. DOI: 10.1016/j.ceca.2022.102586.

References

Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A . Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014; 9(6):e100777. PMC: 4069074. DOI: 10.1371/journal.pone.0100777. View

Oudit G, Kassiri Z, Jiang C, Liu P, Poutanen S, Penninger J . SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009; 39(7):618-25. PMC: 7163766. DOI: 10.1111/j.1365-2362.2009.02153.x. View

Wehbe Z, Hammoud S, Soudani N, Zaraket H, El-Yazbi A, Eid A . Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling. Front Pharmacol. 2020; 11:836. PMC: 7283382. DOI: 10.3389/fphar.2020.00836. View

Zou H, Zhou B, Xu G . SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol. 2017; 16(1):65. PMC: 5434580. DOI: 10.1186/s12933-017-0547-1. View

Feldman E, Savelieff M, Hayek S, Pennathur S, Kretzler M, Pop-Busui R . COVID-19 and Diabetes: A Collision and Collusion of Two Diseases. Diabetes. 2020; 69(12):2549-2565. PMC: 7679769. DOI: 10.2337/dbi20-0032. View

Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H . Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats. J Pharmacol Sci. 2018; 137(2):220-223. PMC: 6050139. DOI: 10.1016/j.jphs.2017.10.006. View

Chen L, Li X, Chen M, Feng Y, Xiong C . The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020; 116(6):1097-1100. PMC: 7184507. DOI: 10.1093/cvr/cvaa078. View

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T, Yokota T . SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. Int J Mol Sci. 2017; 18(5). PMC: 5454992. DOI: 10.3390/ijms18051083. View

10.

Neuen B, Young T, Heerspink H, Neal B, Perkovic V, Billot L . SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019; 7(11):845-854. DOI: 10.1016/S2213-8587(19)30256-6. View

11.

Kosiborod M, Berwanger O, Koch G, Martinez F, Mukhtar O, Verma S . Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. Diabetes Obes Metab. 2020; 23(4):886-896. PMC: 8049025. DOI: 10.1111/dom.14296. View

12.

Azushima K, Morisawa N, Tamura K, Nishiyama A . Recent Research Advances in Renin-Angiotensin-Aldosterone System Receptors. Curr Hypertens Rep. 2020; 22(3):22. DOI: 10.1007/s11906-020-1028-6. View

13.

Mori J, Oudit G, Lopaschuk G . SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolism. Am J Physiol Endocrinol Metab. 2020; 319(1):E43-E47. PMC: 7322507. DOI: 10.1152/ajpendo.00219.2020. View

14.

Gupta K, Kunal S . SGLT-2 inhibitors as cardioprotective agents in COVID-19. Heart Lung. 2020; 49(6):875-876. PMC: 7508492. DOI: 10.1016/j.hrtlng.2020.09.002. View

15.

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B . A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005; 11(8):875-9. PMC: 7095783. DOI: 10.1038/nm1267. View

16.

Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla A . COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020; 13(12):1833-1839. PMC: 7402107. DOI: 10.1016/j.jiph.2020.07.014. View

17.

Cherney D, Perkins B, Soleymanlou N, Xiao F, Zimpelmann J, Woerle H . Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int. 2014; 86(5):1057-8. DOI: 10.1038/ki.2014.246. View

18.

Zhao L, Zhang M, Zhan Z, Qiu M . Does Combination Therapy With SGLT2 Inhibitors and Renin-Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?. Front Cardiovasc Med. 2021; 8:679124. PMC: 8131654. DOI: 10.3389/fcvm.2021.679124. View

19.

Muskiet M, van Raalte D, van Bommel E, van Bommel E, Smits M, Tonneijck L . Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol. 2015; 3(12):928-9. DOI: 10.1016/S2213-8587(15)00424-6. View

20.

Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J . Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018; 15:335-346. PMC: 5756062. DOI: 10.1016/j.redox.2017.12.019. View